Why Tilray Stock Rallied After its Q3 Results

Here’s why Tilray (TSX:TLRY) stock jumped sharply after announcing its Q3 results.

| More on:

What happened?

The shares of Tilray (TSX:TLRY)(NASDAQ:TLRY) rose sharply on Wednesday after the company announced the results for Q3 of its fiscal year 2022. During the intraday trading, the TSX-listed TLRY stock jumped by about 16% yesterday before paring some of the gains in the latter half of the session, as the broader market selloff intensified.

So what?

In the third quarter ended in February 2022, Tilray registered 23% YoY (year-over-year) positive growth in its total revenue to around US$151.9 million. However, its latest quarterly revenue figure missed analysts’ estimate of US$156.8 million by a narrow margin.  While its cannabis segment revenue jumped by 32% YoY, the company registered solid 64% growth in its beverage alcohol revenue. In addition, Tilray’s international market cannabis revenue saw a massive increase.

Despite its lower-than-expected revenue, the cannabis giant pleasantly surprised investors by reporting a second consecutive profitable quarter. Tilray’s Q3 adjusted earnings stood at around US$0.09 per share against Street’s expectation of US$0.08-per-share loss. The company cited a reduction in its “assessment of the contingent consideration owed on the SweetWater transaction” as one of the factors that impacted its profits in the February quarter. These factors seemingly helped the company regain investors’ confidence, triggering a rally in TLRY stock price.

Now what?

Currency headwinds stole about US$7 million from Tilray’s distribution segment revenue in the last quarter as the euro continues to weaken against the U.S. dollar. Apart from this temporary negative factor, Tilray’s latest quarterly financial results largely reflected strong positive growth.

After the completion of the Aphria-Tilray merger in May 2021, Tilray has achieved nearly US$76 million in cost synergies. By the end of May 2022, the company expects to reach its goal of achieving US$80 million Synergy — way ahead of schedule. Also, a massive recent rise in its international market revenue reflects optimism for Tilray’s long-term business growth.

Given these positive developments, long-term investors may consider buying TLRY stock right now. Despite yesterday’s sharp rally, Tilray stock continues to underperform the main Canadian market gauge, as it’s trading with only 2% year-to-date gains.

The Motley Fool has no position in any of the stocks mentioned. Fool contributor Jitendra Parashar has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »